Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$99.73 - $148.48 $2 Million - $2.98 Million
-20,096 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $1.99 Million - $2.79 Million
20,096 New
20,096 $2.79 Million
Q3 2019

Nov 14, 2019

SELL
$37.38 - $49.47 $373,800 - $494,700
-10,000 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $37,044 - $62,386
931 Added 10.27%
10,000 $438,000
Q1 2019

May 14, 2019

BUY
$34.52 - $53.29 $105,596 - $163,014
3,059 Added 50.9%
9,069 $467,000
Q4 2018

Feb 14, 2019

SELL
$29.75 - $42.9 $609,220 - $878,506
-20,478 Reduced 77.31%
6,010 $222,000
Q3 2018

Nov 14, 2018

BUY
$32.79 - $43.0 $528,574 - $693,160
16,120 Added 155.48%
26,488 $995,000
Q2 2018

Aug 14, 2018

SELL
$23.62 - $42.29 $2.4 Million - $4.3 Million
-101,623 Reduced 90.74%
10,368 $410,000
Q1 2018

May 15, 2018

BUY
$22.49 - $34.56 $2.36 Million - $3.62 Million
104,794 Added 1456.08%
111,991 $2.89 Million
Q4 2017

Feb 16, 2018

BUY
$20.44 - $35.56 $147,106 - $255,925
7,197
7,197 $194,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.